Texas Instruments says it is nearing recovery after Q3 sales fell for the eighth straight quarter to $4.15B, down 8.4% YoY, and projects Q4 sales below est.
Ian King / Bloomberg :
Context & Ripple Effects
Texas Instruments’ decline has persisted from the end of its earlier double-digit growth run through a weaker industrial-demand backdrop and into 2024. Its Q2 revenue fell 16% year over year before management’s Q3 outlook roughly matched expectations.
The latest result moderates that rate of decline to 8.4%, supporting management’s recovery framing. But Q4 guidance below estimates shows the improvement has not yet translated into the pace investors expected.
First-order effects
- Texas Instruments enters Q4 with lower expected sales than analysts had modeled, despite reporting its eighth consecutive quarter of year-over-year contraction.
- The smaller Q3 decline versus the 16% Q2 revenue drop gives the company evidence that its downturn is easing, while leaving its near-term outlook constrained.
Second-order effects
- A below-consensus Q4 forecast resets the near-term benchmark for TI’s recovery: investors must distinguish a slowing decline from a return to growth.
- The result reinforces caution around chip demand tied to TI’s end markets, since the company’s recovery signal is accompanied by guidance that still misses expectations.
Third-order effects
- If sequential improvement continues while year-over-year sales remain negative, the semiconductor cycle may shift from broad contraction to a prolonged, uneven normalization rather than a sharp rebound.
- The episode highlights how recovery narratives in cyclical chip markets can arrive before reported growth and forecast momentum fully follow.
The trend: This is one data point in the contracted semiconductor cycle’s transition from steep demand declines toward an uneven recovery.